The FLEX Registry is a research study for people with stage I to III breast cancer. It involves two tests called MammaPrint® and BluePrint, which help doctors understand the cancer better. The study will include around 30,000 patients from over 125 places in the United States. The goal is to gather information that can help find new ways to treat cancer. Doctors will decide the best treatment for each patient based on guidelines. This study will collect health data at different times: when you join, during treatment, and 1, 3, 5, and 10 years after being diagnosed.
- Participants need to have specific tests done and sign a consent form.
- The study doesn't involve new treatments, only observation.
- It lasts for up to 10 years.